Paper Review Records
All Paper Review Records
1 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
232
days
Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial
Authors
Ying Liu; Xiangjiao Meng; Yan Yu; Jianhua Chen; Runxiang Yang; Laiyu Liu; Yanqiu Zhao; Ruifen Tian; Dianming Li; Ruiling Ning; Qingshan Li; Guowu Wu; Li Wang; Xianghui Duan; Xuejie Guo; Yan Hu; Weili Liu; Haifeng LiuShow moreShow less
Affiliations
1. Department of Oncology , Jilin Provincial Cancer Hospital , Changchun, Jilin, P. R. China .; 2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute , Shandong First Medical University and Shandong Academy of Medical Sciences , Jinan, Shandong, P. R. China .; 3. Department of Thoracic Medical Oncology , The Affiliated Cancer Hospital of Harbin Medical University , Harbin, Heilongjiang, P. R. China .; 4. Department of Thoracic Medical Oncology , Hunan Provincial Cancer Hospital , Changsha, Hunan, P. R. China .; 5. Department of Medical Oncology , Yunnan Provincial Cancer Hospital , Kunming, Yunnan, P. R. China .; 6. Department of Respiratory and Critical Care Medicine , Nanfang Hospital Affiliated to Southern Medical University , Guangzhou, Guangdong, P. R. China .; 7. Department of Thoracic Medical Oncology , The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital , Zhengzhou, Henan, P. R. China .; 8. Department of Respiratory Oncology , Shanxi Provincial Cancer Hospital , Taiyuan, Shanxi, P. R. China .; 9. Department of Respiratory and Critical Care Medicine , The First Affiliated Hospital of Bengbu Medical College , Bengbu, Anhui, P. R. China .; 10. Department of Respiratory Medical Oncology , The Affiliated Cancer Hospital of Guangxi Medical University , Nanning, Guangxi Zhuang Autonomous Region, P. R. China .; 11. Department of Oncology , The Affiliated Hospital of Chengde Medical University , Chengde, Hebei, P. R. China .; 12. Department of Medical Oncology , Meizhou People’s Hospital , Meizhou, Guangdong, P. R. China .; 13. Department of Clinical Science , Xuanzhu Biopharmaceutical Co. Ltd. , Beijing, P. R. China .Show moreShow less
FAQ
How long does Cancer Communications take to review a manuscript?
As of 2026-11-19, CrushSCI has only 1 complete review record for Cancer Communications: Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial, received 2026-03-02 and accepted 2026-10-20, a review time of 232 days. With a single record, treat this as indicative only.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
